Regulatory B cells in myasthenia gravis are differentially affected by therapies - Sorbonne Université
Article Dans Une Revue Annals of Clinical and Translational Neurology Année : 2018

Regulatory B cells in myasthenia gravis are differentially affected by therapies

Vuslat Yilmaz
  • Fonction : Auteur
Anthony Behin
  • Fonction : Auteur
  • PersonId : 887996
Jean-François Régnard
  • Fonction : Auteur
Sonia Berrih-Aknin
Rozen Le Panse

Résumé

We analyzed the number and functionality of regulatory B (Breg) cells in well‐defined myasthenia gravis patients. We first showed a decreased number of circulating CD19+CD24++CD38++ Breg cells and an altered functionality of Breg cells in untreated myasthenia gravis patients. Next, we demonstrated that the proportion of circulating Breg cells was restored in myasthenia gravis patients after thymectomy, probably as Breg cells could be sequestered in the myasthenia gravis thymus. In contrast, corticosteroid treatments did not restore and decreased even more the proportion of Breg cells in myasthenia gravis patients. These results clearly demonstrated that two distinct immunomodulatory therapies affect differentially Breg cells.
Fichier principal
Vignette du fichier
Yilmaz_et_al-2018-Annals_of_Clinical_and_Translational_Neurology.pdf (445.36 Ko) Télécharger le fichier
Origine Publication financée par une institution
Loading...

Dates et versions

hal-01942391 , version 1 (03-12-2018)

Licence

Identifiants

Citer

Vuslat Yilmaz, Solène Maillard, Frédérique Truffault, Francis Bolgert, Anthony Behin, et al.. Regulatory B cells in myasthenia gravis are differentially affected by therapies. Annals of Clinical and Translational Neurology, 2018, 5 (11), pp.1408-1414. ⟨10.1002/acn3.645⟩. ⟨hal-01942391⟩
29 Consultations
77 Téléchargements

Altmetric

Partager

More